国家神经系统疾病临床医学研究中心数据管理与共享系统

Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

《国家中心数据管理与共享系统操作说明书 —— 研究者部分》

Triglyceride Glucose Index and Prognosis of Patients With Ischemic Stroke

第一作者：Yimo Zhou

通讯作者：Yongjun Wang

insulin resistance triglyceride glucose index ischemic stroke stroke recurrence prognosis

基本信息

  • 负责人：Yimo Zhou
  • 数据来源： Golden Bridge
  • 论文编号：GOLDEN BRIDGE20200133
  • 发表时间：2020-06-10

2020-06-10

已发表文章

发表杂志：Frontiers in Neurology

发表类型: Original Research

影响因子(IF): 4.003

PMID: 32587566 Pubmed原文链接 全文下载

主要研究背景及目的

The triglyceride glucose index (TyG index) has been proposed as a simple and credible surrogate marker of insulin resistance. However, it is unclear whether TyG index correlates with adverse clinical outcomes in patients with ischemic stroke. Accordingly, this study aimed to explore the relationship between baseline TyG index and clinical outcomes of ischemic stroke individuals.

方法

We included eligible subjects with ischemic stroke from the China National Stroke Registry II for the current analysis. TyG index was calculated and divided into quartiles to explore the relationship with the outcomes of ischemic stroke. Outcomes included stroke recurrence, all-cause mortality, poor functional outcome at 12 months, and neurologic worsening at discharge. Multivariable Cox regression and logistic regression models were performed to explore the correlation of baseline TyG index with the outcomes.

结论

TyG index representing insulin resistance was associated with an increased risk of stroke recurrence, all-cause mortality, and neurologic worsening in patients with ischemic stroke.

主要结果

Among the 16,310 patients enrolled in the study, the average age was 64.83 ±11.9 years, and 63.48%weremen. The median TyG index was 8.73 (interquartile range, 8.33–9.21). After adjustment for multiple potential covariates, the fourth quartile of TyG index was associated with an increased risk of stroke recurrence (adjusted HR, 1.32; 95% CI, 1.11–1.57; P = 0.002), all-cause mortality (adjusted HR, 1.25; 95%CI, 1.06–1.47; P = 0.01) at 12-month follow-up, and neurological worsening (adjusted OR, 1.26; 95% CI, 1.02–1.55; P = 0.03) at discharge, but not poor functional outcome compared with the first quartile.